Ocugen
OCGN | NASDAQ
$0.77
-$0.06 (-6.98%)
At close: Nov 16, 2026, 4:00 PM ET
$0.77
$0.00 (+0.48%)
After-hours:
Nov 16, 2026, 7:54 PM ET
Ocugen Company Profile
Company profile explainedCompany Profile
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Key Executives
| Name | Position |
|---|---|
| Shankar Musunuri | Co-Founder, Chief Executive Officer & Chairman |
| Arun Upadhyay | Chief Scientific Officer and Head of Research & Development |
| Chris Clark | VP of Corporate Communications |
| Durgaprasad Annavajjula | Vice President, Head of Program Management & Chief of Staff |
| John Kouch | General Counsel |
| Jyothy Pillai | Vice President & Head of Regulatory & Quality |
| Kristen Craft | Head of People & Culture |
| Mohamed Genead | Chief Medical Officer |
| Paul Staid | Executive Vice President of Operations |
| Rita Johnson-Greene | CFO & Principal Accounting Officer |
| Vijay Tammara | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2026 | 8-K | Current Report |
| Oct 15, 2026 | 8-K | Current Report |
| Oct 13, 2026 | 4 | Filing |
| Oct 06, 2026 | 8-K | Current Report |
| Sep 23, 2026 | 8-K | Current Report |
| Sep 11, 2026 | 4 | Filing |
| Sep 08, 2026 | 8-K | Current Report |
| Aug 14, 2026 | DEFA14A | Filing |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Ocugen
| Country | United States |
| IPO Date | Dec 3, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Shankar Musunuri |
Contact Details
263 Great Valley Parkway Malvern,
Pennsylvania 19355 United States
Stock Details
| Ticker Symbol | OCGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001372299 |
| CUSIP Number | 67577C105 |
| ISIN Number | US67577C1053 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove OCGN